"Polypill" to Lower Risk of Heart Disease UK researchers are proposing pushing an off-patent "polypill" on all citizens over the age of 55 that they believe will add significant years of life to those who will take it. Based on published randomized trials and studies on the component drugs, the researchers extrapolate the combined effects will stave off heart disease by combating the four main risk factors: high cholesterol, high blood pressure, high homocysteine levels, and poor blood platelet function. The proposed polypill will contain the following: "a statin (for example, atorvastatin (daily dose 10 mg) or simvastatin (40 mg)); three blood pressure lowering drugs (for example, a thiazide, a beta blocker, and an angiotensin converting enzyme inhibitor), each at half standard dose; folic acid (0.8 mg); and aspirin (75 mg)." This drug could be produced cheaply because the patents on the component drugs are either expired or will expire soon. Because "age is a more powerful predictor of cardiovascular disease than the risk factors usually considered" this drug cocktail could be said in a sense to combat aging itself. Such preventative regimens could very well blossom from this investigate-clinical-trial phase into a broad means of offsetting aging by decades in all people. Hopefully the results from trials with the polypill will foreshadow such regimens.